Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 9/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7219364 | 0.90 | DGAT1 (0.55) | DGAT1HDAC2HDAC1HDAC8HDAC3 | |
| SCHEMBL7170747 | 0.89 | HDAC1 (0.46) | DGAT1HDAC2HDAC1HDAC8HDAC3 | |
| SCHEMBL7168738 | 0.85 | HDAC1 (0.46) | DGAT1HDAC2HDAC1HDAC8HDAC3 | |
| SCHEMBL7167869 | 0.84 | HDAC1 (0.43) | DGAT1HDAC2HDAC1HDAC8HDAC3 | |
| SCHEMBL7220507 | 0.83 | HDAC1 (0.40) | DGAT1HDAC2HDAC1HDAC8HDAC3 | |
| SCHEMBL7227385 | 0.81 | HDAC1 (0.45) | DGAT1HDAC2HDAC1HDAC8HDAC3 | |
| SCHEMBL7167834 | 0.80 | HDAC1 (0.48) | HDAC2HDAC1HDAC8HDAC3HDAC6 | |
| SCHEMBL7226924 | 0.79 | HDAC6 (0.48) | DGAT1HDAC2HDAC1HDAC8HDAC3 | |
| SCHEMBL7226605 | 0.79 | HDAC1 (0.48) | DGAT1HDAC2HDAC1HDAC8HDAC3 | |
| SCHEMBL7166455 | 0.79 | HDAC1 (0.46) | DGAT1HDAC2HDAC1HDAC8HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349830-A1 | TETRALONE DERIVATIVES AS ANTITUMOR AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6531472-B2 | Has histone deacetylase (HDAC) inhibitory activity which is useful in cancer treatment | HOFFMAN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2002046144-A1 | TETRALONE DERIVATIVES AS ANTITUMOR AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-13 | — | — | WO | disclosed |
| US-20020065282-A1 | Tetralone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065282-A1 | Tetralone derivatives | HDAC1, HDAC5, HDAC3 | DGAT1 4030/4885HDAC2 7/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.